Mission Creek Capital Partners Inc. Sells 406 Shares of Johnson & Johnson $JNJ

Mission Creek Capital Partners Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ) by 1.2% in the first quarter, Holdings Channel.com reports. The fund owned 34,253 shares of the company’s stock after selling 406 shares during the quarter. Johnson & Johnson makes up about 1.2% of Mission Creek Capital Partners Inc.’s investment portfolio, making the stock its 22nd largest position. Mission Creek Capital Partners Inc.’s holdings in Johnson & Johnson were worth $5,681,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Johnson & Johnson by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company’s stock worth $38,800,371,000 after acquiring an additional 1,170,120 shares in the last quarter. Northern Trust Corp lifted its holdings in Johnson & Johnson by 0.4% in the 1st quarter. Northern Trust Corp now owns 30,943,820 shares of the company’s stock worth $5,131,723,000 after purchasing an additional 130,645 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Johnson & Johnson by 26.4% during the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock worth $3,844,580,000 after purchasing an additional 4,842,582 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Johnson & Johnson by 3.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company’s stock worth $3,133,602,000 after buying an additional 712,181 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its holdings in Johnson & Johnson by 2.5% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company’s stock worth $3,031,955,000 after acquiring an additional 448,666 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on JNJ. UBS Group increased their price target on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a “buy” rating in a report on Thursday, July 17th. Royal Bank Of Canada upped their price target on Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. Bank of America lifted their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a report on Thursday, July 17th. Citigroup raised their target price on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “buy” rating in a research report on Thursday, August 21st. Finally, Wall Street Zen cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 18th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $176.29.

Johnson & Johnson Trading Up 0.1%

Shares of Johnson & Johnson stock opened at $176.69 on Thursday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $181.16. The stock has a market capitalization of $425.52 billion, a P/E ratio of 18.90, a price-to-earnings-growth ratio of 2.25 and a beta of 0.41. The company has a 50-day simple moving average of $164.95 and a 200 day simple moving average of $159.72. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period in the prior year, the company earned $2.82 EPS. Johnson & Johnson’s revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.